Physician profile
James Agresti
NPI 1306931837
$1,987.43
in general payments reported to CMS, 2019-2025
28 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $284 · 2021: $358 · 2022: $152 · 2023: $249 · 2024: $205 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $299.40 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $219.66 | 2019-2025 | Jardiance, Mounjaro |
| Fresenius USA Marketing, INC. | $175.98 | 2019-2024 | Velphoro |
| Novartis Pharmaceuticals Corporation | $174.47 | 2019-2023 | |
| Pfizer INC. | $147.27 | 2019-2023 | |
| Novo Nordisk INC | $120.03 | 2020-2025 | Ozempic, Rybelsus |
| Amgen INC. | $115.60 | 2019-2025 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $88.47 | 2019-2020 | |
| Akebia Therapeutics INC | $76.72 | 2019-2024 | Auryxia, Vafseo |
| Kowa Pharmaceuticals America, INC. | $65.97 | 2022-2023 | Seglentis, Livalo |
| Almatica Pharma LLC | $59.42 | 2023-2024 | Loreev Xr, Gralise |
| Aytu Biopharma, INC. | $53.47 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $47.44 | 2024-2025 | Kristalose |
| Merck Sharp & Dohme LLC | $43.82 | 2019-2024 | Lagevrio, Dificid |
| Mallinckrodt Hospital Products INC. | $41.40 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $32.31 | 2023-2024 | Tarpeyo |
| Sumitomo Pharma America, INC. | $29.60 | 2024 | Gemtesa |
| Endo Pharmaceuticals INC. | $28.85 | 2020 | |
| Sunovion Pharmaceuticals INC. | $25.06 | 2019-2020 | |
| Tactile Systems Technology INC | $23.37 | 2025 | Flexitouch Plus, Nimbl |
| Travere Therapeutics, INC. | $17.81 | 2025 | |
| Abbott Laboratories | $17.38 | 2023 | Freestyle Libre 3 |
| Vifor Pharma, INC. | $16.82 | 2023 | Veltassa, Korsuva |
| Xeris Pharmaceuticals, INC. | $15.70 | 2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $14.60 | 2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $13.12 | 2022 | |
| Horizon Therapeutics Plc | $12.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Agresti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.